Publication Name	World Journal of Gastroenterology
Manuscript ID	66039
Country	Canada

Received	2021-03-19 20:39
Peer-Review Started	2021-03-19 20:43
To Make the First Decision
Return for Revision	2021-05-01 03:40
Revised	2021-05-08 02:03
Second Decision	2021-08-31 03:34
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-08-31 09:11
Articles in Press	2021-08-31 09:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-09-26 11:20
Publish the Manuscript Online	2021-09-29 11:12

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring
Manuscript Source	Invited Manuscript
All Author List	Farah Albader, Petra Anna Golovics, Lorant Gonczi, Talat Bessissow, Waqqas Afif and Peter Laszlo Lakatos
ORCID	Author(s) ORCID Number Farah Albader http://orcid.org/0000-0003-2657-4558 Petra Anna Golovics http://orcid.org/0000-0003-3195-183X Lorant Gonczi http://orcid.org/0000-0002-8819-6460 Talat Bessissow http://orcid.org/0000-0003-2610-1910 Waqqas Afif http://orcid.org/0000-0001-6869-0982 Peter Laszlo Lakatos http://orcid.org/0000-0002-3948-6488
Funding Agency and Grant Number
Corresponding Author	Peter Laszlo Lakatos, MD, PhD, Professor, Staff Physician, Division of Gastroenterology, McGill University, 1650 Cedar Avenue, Montreal H3G 1A4, Quebec, Canada. kislakpet99@gmail.com
Key Words	Therapeutic drug monitoring; Inflammatory bowel disease; Biologic therapies; Loss of response; Reactive; Proactive
Core Tip	In this review, we discuss the existing studies that looked at both proactive and reactive therapeutic drug monitoring (TDM) and concluded that in current practice, reactive TDM has been shown to be useful. When used as an adjunct to clinical assessment and biomarkers in patients with treatment failure, TDM has proven to be a valuable tool for subsequent management.
Publish Date	2021-09-29 11:12
Citation	Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247
URL	https://www.wjgnet.com/1007-9327/full/v27/i37/6231.htm
DOI	https://dx.doi.org/10.3748/wjg.v27.i37.6231

Full Article (PDF)	WJG-27-6231.pdf
Full Article (Word)	WJG-27-6231.docx
Manuscript File	66039_Auto_Edited-JLW.docx
Answering Reviewers	66039-Answering reviewers.pdf
Audio Core Tip	66039-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	66039-Conflict-of-interest statement.pdf
Copyright License Agreement	66039-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	66039-Language certificate.pdf
Peer-review Report	66039-Peer-review(s).pdf
Scientific Misconduct Check	66039-Scientific misconduct check.pdf
Scientific Editor Work List	66039-Scientific editor work list.pdf
CrossCheck Report	66039-CrossCheck report.pdf